Compared to chemotherapy, the SAPPHIRE study did not satisfy its primary endpoint. According to findings from the phase III th SAPPHIRE trial presented on October
The phase III MANTRA trial reported disappointing results, but biomarker-based approaches still offer promise for MDM2 inhibition in solid tumors. Results presented at the ESMO
In two trials, progression-free survival was longer with tumor-specific chemotherapy than with standard chemotherapy, but more research is required to enhance the prognosis for these
Long-term data presented at the ESMO Congress confirm the efficacy of PD-1 inhibitors in this setting, which is comparable to that documented for triple-negative breast
Friday, October 20th,2023, Madrid ,Spain: Long-term data presented at the ESMO Congress confirm the efficacy of PD-1 inhibitors in this setting, which is comparable to
The JCOG1611-GENERATE trial results stimulate the debate over the optimal treatment option in this setting. A planned interim analysis on 527 patients in the multicenter,
Sunday, October 22nd 2023, Madrid, Spain : Patients with this aggressive disease may benefit from neoadjuvant, perioperative, targeted, and combined treatment approaches, but additional research
Tuesday October 24th 2023, Madrid, Spain: This paper was presented on October 24th 2023 at the ESMO Congress 2023 at Madrid Anti-HER2 therapy combined with
Long-term data presented at the ESMO Congress confirm the efficacy of PD-1 inhibitors in this setting, which is comparable to that documented for triple-negative breast
This paper was presented on October 20 at the ESMO Congress 2023 at Madrid. Molecular alterations (MA) may influence therapeutic approaches, but in Spain there